RESUMO
The serum fructosamine assay is a new commercially available test designed to measure serum glycated protein as an index of glycemic control in diabetes. The test relies on the ability of glucose bound to protein with a ketamine linkage (fructosamine) to act as a reducing agent in alkaline solution. Serum fructosamine activity was studied in 61 Type I diabetic patients attending a 2-week American Diabetes Association sponsored diabetic camp for children. The initial fructosamine level was found to correlate well with the initial HgA1C value (r = .82, p less than .001). To assess if mean blood glucose correlated with these objective parameters, the authors performed capillary blood glucoses preprandially and at bedtime on all 61 diabetic campers during the 2-week period of observation and reassessed serum fructosamine activity and HgA1C on day 14 of camp. We found the HgA1C and fructosamine correlated well with the mean daily blood glucose obtained during the preceding week (r = .45, p less than .01 and r = .58, p less than .01) respectively. Our data suggest that the serum fructosamine is as effective as the HgA1C in correlating to mean blood glucose control in this cross-sectional study of Type I diabetic patients.
